Deciphering the Therapeutic Potential of Novel Pentyloxyamide-Based Class I, IIb HDAC Inhibitors against Therapy-Resistant Leukemia.

Autor: Fischer F; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Schliehe-Diecks J; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Tu JW; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Gangnus T; Individualized Pharmacotherapy, Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany., Ho YL; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Hebeis M; Bioinorganic Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Egerlandstr. 1, 91058 Erlangen, Germany., Alves Avelar LA; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Scharov K; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Watrin T; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Kemkes M; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Stachura P; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.; Department of Molecular Medicine II, Medical Faculty, Heinrich Heine University, Universitätsstraße 1, 40225 Düsseldorf, Germany., Daugs K; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Biermann L; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Kremeyer J; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Horstick N; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Span I; Bioinorganic Chemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Egerlandstr. 1, 91058 Erlangen, Germany., Pandyra AA; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.; Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany., Borkhardt A; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Gohlke H; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.; Institute of Bio- and Geosciences (IBG-4: Bioinformatics), Forschungszentrum Jülich, 52425 Jülich, Germany., Kassack MU; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Burckhardt BB; Individualized Pharmacotherapy, Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, 48149 Münster, Germany., Bhatia S; Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany., Kurz T; Institute of Pharmaceutical und Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Dec 12; Vol. 67 (23), pp. 21223-21250. Date of Electronic Publication: 2024 Nov 27.

The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines.

Autor: Bollmann LM; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany., Skerhut AJ; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany., Asfaha Y; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany., Horstick N; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany., Hanenberg H; Department of Otorhinolaryngology and Head/Neck Surgery, Heinrich Heine University, 40225 Duesseldorf, Germany., Hamacher A; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany., Kurz T; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany., Kassack MU; Institute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, Germany.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Nov 02; Vol. 23 (21). Date of Electronic Publication: 2022 Nov 02.

The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells.

Autor: Pradel, Laura S.¹ (AUTHOR) laura.pradel@hhu.de, Ho, Yu-Lin¹ (AUTHOR) yu-lin.ho@hhu.de, Gohlke, Holger^1,2 (AUTHOR) gohlke@uni-duesseldorf.de, Kassack, Matthias U.¹ (AUTHOR) matthias.kassack@uni-duesseldorf.de

Publikováno v: International Journal of Molecular Sciences. Aug2024, Vol. 25 Issue 15, p8455. 26p.

Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors.

Autor: Frühauf, Anton¹ (AUTHOR) anton.fruehauf@h-da.de, Behringer, Martin¹ (AUTHOR), Meyer-Almes, Franz-Josef¹ (AUTHOR) franz-josef.meyer-almes@h-da.de

Publikováno v: Molecules. Aug2023, Vol. 28 Issue 15, p5686. 36p.

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells.

Autor: Schrenk, Christian¹ (AUTHOR), Bollmann, Lukas M.¹ (AUTHOR), Haist, Corinna² (AUTHOR), Bister, Arthur² (AUTHOR), Wiek, Constanze² (AUTHOR), Wecker, Maria³ (AUTHOR), Roth, Dennis³ (AUTHOR), Petzsch, Patrick⁴ (AUTHOR), Köhrer, Karl⁴ (AUTHOR), Hamacher, Alexandra¹ (AUTHOR), Hanenberg, Helmut^2,5 (AUTHOR), Fluegen, Georg³ (AUTHOR), Kassack, Matthias U.¹ (AUTHOR) matthias.kassack@hhu.de

Publikováno v: International Journal of Molecular Sciences. Mar2023, Vol. 24 Issue 6, p5553. 20p.